ZA200810850B - High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity - Google Patents

High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity

Info

Publication number
ZA200810850B
ZA200810850B ZA200810850A ZA200810850A ZA200810850B ZA 200810850 B ZA200810850 B ZA 200810850B ZA 200810850 A ZA200810850 A ZA 200810850A ZA 200810850 A ZA200810850 A ZA 200810850A ZA 200810850 B ZA200810850 B ZA 200810850B
Authority
ZA
South Africa
Prior art keywords
high affinity
humanized anti
reduced immunogenicity
blocking antibodies
affinity human
Prior art date
Application number
ZA200810850A
Other languages
English (en)
Inventor
Andreas Menrad
Joerg Willuda
Klaus Bosslet
Dieter Zopft
Heike Petrul
Stefan Steidl
Josef Prassler
Corinne Petit-Frere
Original Assignee
Bayer Schering Pharma Ag
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Morphosys Ag filed Critical Bayer Schering Pharma Ag
Publication of ZA200810850B publication Critical patent/ZA200810850B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
ZA200810850A 2006-05-24 2008-12-23 High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity ZA200810850B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06010779 2006-05-24

Publications (1)

Publication Number Publication Date
ZA200810850B true ZA200810850B (en) 2010-05-26

Family

ID=38659612

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200810850A ZA200810850B (en) 2006-05-24 2008-12-23 High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity

Country Status (23)

Country Link
US (1) US20090081207A1 (ja)
EP (1) EP2032605A2 (ja)
JP (1) JP2009537158A (ja)
KR (1) KR20090027218A (ja)
CN (1) CN101495515A (ja)
AR (1) AR061107A1 (ja)
AU (1) AU2007253586A1 (ja)
BR (1) BRPI0711796A2 (ja)
CA (1) CA2652886A1 (ja)
CL (1) CL2007001488A1 (ja)
CR (1) CR10456A (ja)
DO (2) DOP2007000101A (ja)
EA (1) EA200802348A1 (ja)
EC (1) ECSP088909A (ja)
MA (1) MA30425B1 (ja)
MX (1) MX2008014910A (ja)
NO (1) NO20085362L (ja)
PE (1) PE20080100A1 (ja)
TN (1) TNSN08469A1 (ja)
TW (1) TW200817433A (ja)
UY (1) UY30362A1 (ja)
WO (1) WO2007134876A2 (ja)
ZA (1) ZA200810850B (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053577A2 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
HUE025989T2 (hu) 2006-03-21 2016-05-30 Genentech Inc Alfa5béta1-antagonistákat magában foglaló kombinációs terápia
CL2008002856A1 (es) 2007-09-26 2009-01-16 Genentech Inc Anticuerpo novedoso (anticuerpo anti-integrina a5b1; mol}ecula de ácido nucleico que lo codifica; vector y célula huesped; método de producción; composición farmacéutica que lo comprende; su uso para inhibir la angiogénesis y/o permeabilidad vascular y cáncer entre otras patologías; y método de detección de la integrina a5b1).
EP2641612A1 (en) * 2008-02-05 2013-09-25 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
RU2579897C2 (ru) 2008-09-26 2016-04-10 Онкомед Фармасьютикалс, Инк. Агенты, связывающие рецептор "frizzled", и их применение
CA2742861A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
US20120114667A1 (en) * 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
RU2011142974A (ru) 2009-03-25 2013-04-27 Дженентек, Инк. НОВЫЕ АНТИТЕЛА ПРОТИВ α5β1 И ИХ ПРИМЕНЕНИЕ
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
CN103003296A (zh) * 2010-07-09 2013-03-27 阿菲博迪公司 多肽
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
MY171125A (en) 2012-03-13 2019-09-26 Respivert Ltd Crystalline pi3 kinase inhibitors
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
CA2896331C (en) * 2012-12-26 2023-08-01 Oncosynergy, Inc. Anti-integrin .beta.1 antibody compositions and methods of use thereof
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CA2987884C (en) * 2015-06-28 2023-01-03 Allgenesis Biotherapeutics Inc. Fusion peptides comprising disintegrin binding to integrin .alpha.v.beta.x or .alpha.5.beta.1 and their use in treating an angiogenic disease
EP3916014A4 (en) * 2019-07-24 2022-10-26 Korea Basic Science Institute SINGLE DOMAIN ANTIBODIES TARGETED AGAINST AVSS3 INTEGRIN
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013495A (en) * 1994-10-21 2000-01-11 The Scripps Research Institute Methods of use for integrin B1C cell growth inhibitor
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
NZ540562A (en) * 2002-11-26 2008-04-30 Pdl Biopharma Inc Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis
CA2560508A1 (en) * 2004-03-24 2005-10-06 Pdl Biopharma, Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
HUE025989T2 (hu) * 2006-03-21 2016-05-30 Genentech Inc Alfa5béta1-antagonistákat magában foglaló kombinációs terápia

Also Published As

Publication number Publication date
CL2007001488A1 (es) 2008-01-04
MA30425B1 (fr) 2009-05-04
DOP20070101A (es) 2007-12-30
MX2008014910A (es) 2009-01-23
WO2007134876A8 (en) 2009-07-02
JP2009537158A (ja) 2009-10-29
UY30362A1 (es) 2008-01-02
CN101495515A (zh) 2009-07-29
EA200802348A1 (ru) 2009-08-28
DOP2007000101A (es) 2007-12-31
AU2007253586A1 (en) 2007-11-29
EP2032605A2 (en) 2009-03-11
WO2007134876A3 (en) 2008-03-27
TW200817433A (en) 2008-04-16
TNSN08469A1 (en) 2010-04-14
PE20080100A1 (es) 2008-04-18
CA2652886A1 (en) 2007-11-29
CR10456A (es) 2009-02-26
ECSP088909A (es) 2008-12-30
KR20090027218A (ko) 2009-03-16
WO2007134876A2 (en) 2007-11-29
AR061107A1 (es) 2008-08-06
BRPI0711796A2 (pt) 2011-12-06
US20090081207A1 (en) 2009-03-26
NO20085362L (no) 2009-02-23

Similar Documents

Publication Publication Date Title
ZA200810850B (en) High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity
HRP20181969T1 (hr) Humanizirana protutijela protiv čimbenika d i njihova upotreba
IL240245A0 (en) Antibodies against 5t4 and their uses
HK1208228A1 (en) Antibodies and immunoconjugates and uses therefor
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
AP2809A (en) Anti-Alpha2 Integrin antibodies and their uses
HK1182721A1 (zh) 抗體和免疫偶聯物及其用途
IL194266A0 (en) Anti-igf-ir antibodies and uses thereof
IL193922A0 (en) Anti-tat226 antibodies and immunoconjugates
ZA201001260B (en) Immunogenic polypeptides and monoclonal antibodies
EP2077325A4 (en) MONOCLONAL ANTIBODY AND ITS USE